Cite
HARVARD Citation
Friedlander, M. et al. (n.d.). 224OPatient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of oncology. p. . [Online].